Sivia Capital Partners LLC Has $286,000 Holdings in Sanofi (NASDAQ:SNY)

Sivia Capital Partners LLC reduced its holdings in Sanofi (NASDAQ:SNY) by 16.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,937 shares of the company’s stock after selling 1,128 shares during the quarter. Sivia Capital Partners LLC’s holdings in Sanofi were worth $286,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Northwest Investment Counselors LLC bought a new position in Sanofi during the 3rd quarter worth about $29,000. Concord Wealth Partners raised its position in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares during the last quarter. Fortitude Family Office LLC lifted its stake in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares in the last quarter. Sunbelt Securities Inc. lifted its stake in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in Sanofi during the 2nd quarter worth approximately $51,000. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

NASDAQ SNY traded down $0.16 on Monday, hitting $48.57. 1,738,326 shares of the stock were exchanged, compared to its average volume of 2,274,497. The business’s fifty day moving average is $48.70 and its 200 day moving average is $52.11. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a market capitalization of $123.26 billion, a PE ratio of 24.78, a P/E/G ratio of 1.23 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the company posted $2.55 earnings per share. Research analysts anticipate that Sanofi will post 4.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on SNY shares. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.